Johnson & Johnson (NYSE: JNJ) announced that its Phase 3 PROTEUS study demonstrated that apalutamide combined with hormone therapy reduced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE